CRISPR's Expanding Role: Beyond Gene Editing in Diagnostics and Epigenetic Control

CRISPR technology has evolved significantly beyond gene editing, now offering powerful applications in rapid disease diagnostics and precise epigenetic control of gene expression without altering DNA sequences. Its versatility continues to expand into areas like RNA editing and live-cell imaging, promising broad biotechnological advancements.

David Grossman

October 1, 2026 · 5 min read

Originally recognized for its revolutionary capabilities in gene editing, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has rapidly evolved, demonstrating a broad range of applications that extend far beyond altering DNA sequences. This versatile technology now plays a significant role in areas such as disease diagnostics, the precise control of gene expression without changing underlying DNA, and various other biotechnological advancements. The potential of CRISPR technology is far from reaching its limits, as researchers continue to explore how different CRISPR-associated (Cas) enzymes can be harnessed to detect specific nucleic acid sequences, modulate epigenetic markers, and even visualize genetic material within living cells. This rapid expansion highlights the technology's immense potential across scientific and medical fields, as detailed in a review published by Mary Ann Liebert, Inc., publishers.

CRISPR in Diagnostics: Rapid and Specific Detection

CRISPR-based technologies have emerged as powerful tools for disease diagnostics, offering rapid and accurate detection of specific nucleic acid sequences associated with various conditions. These diagnostic platforms leverage the highly specific target recognition activity of CRISPR-associated nucleases, such as Cas12 and Cas13, to identify DNA or RNA sequences with exceptional sensitivity and programmability. The core principle often involves a guide RNA that directs a Cas enzyme to a complementary target sequence. Upon successful binding to the target, some Cas enzymes undergo a conformational change that activates a non-specific "collateral cleavage" activity.

This means they begin to cut not only the intended target but also nearby non-specific reporter molecules, which are typically labeled with a fluorescent or colorimetric tag. The cleavage of these reporters generates a detectable signal, indicating the presence of the target nucleic acid. This approach has expanded beyond infectious disease detection to include genetic disease screening and precision molecular diagnostics, as noted by Synthego.

Comparing Key CRISPR-Based Diagnostic Platforms

Overview of CRISPR-based diagnostic systems and their operational principles.
Diagnostic Platform/System	Key Cas Enzyme	Mechanism/Principle	Key Advantage(s)
SHERLOCK (Specific High-sensitivity Enzymatic Reporter UnLOCKing)	Cas13 enzymes	Detects specific RNA sequences. Upon target RNA binding, Cas13 activates collateral cleavage of nearby reporter molecules, leading to a detectable signal.	Offers high sensitivity, specificity, and rapid detection for various targets, including viral infections and genetic mutations.
DETECTR (DNA Endonuclease-Targeted CRISPR Trans Reporter)	Cas12 enzymes	Detects specific DNA sequences. Upon target DNA binding, Cas12 activates collateral cleavage of nearby reporter molecules, generating a measurable signal.	Provides high sensitivity, specificity, and rapid detection for various targets, such as viral infections and genetic mutations.
STOPCovid	Cas12 enzymes	A Cas12-based approach designed for rapid viral detection. It leverages the DNA-targeting capabilities of Cas12 for simplified, rapid readouts.	Focuses on simplified, rapid readouts suitable for scalable testing workflows, expanding to genetic disease detection and molecular screening.

Platforms like SHERLOCK (Specific High-sensitivity Enzymatic Reporter UnLOCKing) utilize Cas13 enzymes, which are RNA-targeting. When a guide RNA directs Cas13 to a specific RNA sequence, the enzyme binds and activates its collateral cleavage activity, cutting nearby reporter molecules and producing a detectable signal. This system offers high sensitivity, specificity, and rapid detection for various targets, including viral infections and genetic mutations, according to a review in PMC. Similarly, DETECTR (DNA Endonuclease-Targeted CRISPR Trans Reporter) employs Cas12 enzymes, which are DNA-targeting. Upon target DNA recognition, Cas12 also exhibits collateral activity, cleaving reporter molecules to generate a measurable signal. This provides high sensitivity, specificity, and rapid detection for targets like viral infections and genetic mutations.

Another Cas12-based system, STOPCovid, was developed for rapid viral detection, emphasizing simplified and quick readouts suitable for scalable testing workflows. While initially accelerated by the urgent need for viral detection, CRISPR diagnostics have since expanded far beyond infectious diseases, now being extended into broader applications such as genetic disease detection and precision molecular screening. These systems collectively highlight how CRISPR's precise targeting capabilities can be adapted for highly sensitive and specific diagnostic applications, offering significant advancements in disease detection.

Epigenetic Modulation: Controlling Gene Expression Without DNA Alteration

Beyond directly editing the genetic code, CRISPR technology has opened new avenues for controlling gene expression through epigenetic modulation. Epigenetics refers to heritable changes in gene activity that do not involve alterations to the underlying DNA sequence itself. Instead, these changes involve chemical modifications to DNA or associated proteins (like histones) that influence how genes are read and expressed. CRISPR systems can be engineered to influence these epigenetic marks, effectively "dialing up" or "dialing down" the effect of a gene without making permanent changes to the DNA sequence. This capability is highlighted in a review exploring the diversification of the CRISPR toolbox.

This is primarily achieved by using a modified version of the Cas enzyme, often referred to as a "dead" Cas enzyme (dCas). Unlike its wild-type counterpart, dCas has been engineered to lack the cutting activity but retains its ability to bind to specific DNA or RNA sequences when guided by a guide RNA. By fusing dCas enzymes with epigenetic modifiers—proteins that add or remove chemical tags on DNA or associated proteins—researchers can precisely target these modifiers to specific genomic locations.

For instance, a dCas enzyme fused with an activator protein can be directed to a gene's promoter region to increase its expression, while a dCas fused with a repressor protein can decrease expression. This allows for the activation or repression of genes without making permanent changes to the DNA sequence. Such temporary and reversible control over gene activity offers a powerful tool for studying gene function and holds significant potential for therapeutic interventions where altering the DNA sequence might be undesirable or unnecessary. This approach represents a sophisticated way to manipulate cellular processes by influencing how genes are read and expressed.